RE:Moody's Announces Credit NegativeI posted that last week, it's not 25-50 million and they didn't lose their Moody's rating. But nice try Yolanda. The fact of the matter is that if a company went to the expense of FDA approval and regulatory process to introduce a generic of nilandron then that shows the market for this drug is growing and can handle two formulations. Sometimes competition has a healthy impact on a drug if the market demand is growing. Nilandron is about 2.7% of Cxr revenue, assuming they lose half that, which is beyond worst case scenario, they lose 1.4% of total revenue which accounts for about 15 million. Anyone can read the Moody's article and judge for themselfs. And I think this will give Cxr a chance to raise the price of nilandron which will make up for any lost revenue.